Earnings ·
Reports Q3 net loss of $40.2M; raises ~$410.7M via equity and convertible notes
RAPPRapport Therapeutics, Inc.
Rapport Therapeutics reported a third-quarter net loss of $40.2 million, compared to $26.9 million in the prior year period. Research and development expenses rose to $34.3 million from $22.3 million, while selling, general and administrative costs increased to $9.8 million from $7.7 million. The company ended the quarter with $395.0 million in cash, cash equivalents, and short-term investments. In October 2026, Rapport completed an underwritten public offering of common stock and convertible senior notes due 2032, along with a concurrent private placement, generating approximately $410.7 million in net proceeds. Additionally, the company sold roughly $10 million of shares via its at-the-market program in November 2026. The firm is a clinical-stage biotechnology company dedicated to discovering and developing small molecule precision medicines for neurological and psychiatric disorders.